Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 78


JNK and PTEN cooperatively control the development of invasive adenocarcinoma of the prostate.

Hübner A, Mulholland DJ, Standen CL, Karasarides M, Cavanagh-Kyros J, Barrett T, Chi H, Greiner DL, Tournier C, Sawyers CL, Flavell RA, Wu H, Davis RJ.

Proc Natl Acad Sci U S A. 2012 Jul 24;109(30):12046-51. doi: 10.1073/pnas.1209660109. Epub 2012 Jul 2.


c-Jun NH(2)-terminal kinase mediates leptin-stimulated androgen-independent prostate cancer cell proliferation via signal transducer and activator of transcription 3 and Akt.

Miyazaki T, Bub JD, Iwamoto Y.

Biochim Biophys Acta. 2008 Oct;1782(10):593-604. doi: 10.1016/j.bbadis.2008.07.005. Epub 2008 Aug 5.


Identification of the JNK signaling pathway as a functional target of the tumor suppressor PTEN.

Vivanco I, Palaskas N, Tran C, Finn SP, Getz G, Kennedy NJ, Jiao J, Rose J, Xie W, Loda M, Golub T, Mellinghoff IK, Davis RJ, Wu H, Sawyers CL.

Cancer Cell. 2007 Jun;11(6):555-69.


Temporally controlled ablation of PTEN in adult mouse prostate epithelium generates a model of invasive prostatic adenocarcinoma.

Ratnacaram CK, Teletin M, Jiang M, Meng X, Chambon P, Metzger D.

Proc Natl Acad Sci U S A. 2008 Feb 19;105(7):2521-6. doi: 10.1073/pnas.0712021105. Epub 2008 Feb 11.


The mitogen-activated protein kinase phosphatase vaccinia H1-related protein inhibits apoptosis in prostate cancer cells and is overexpressed in prostate cancer.

Arnoldussen YJ, Lorenzo PI, Pretorius ME, Waehre H, Risberg B, Maelandsmo GM, Danielsen HE, Saatcioglu F.

Cancer Res. 2008 Nov 15;68(22):9255-64. doi: 10.1158/0008-5472.CAN-08-1224.


Sprouty2, PTEN, and PP2A interact to regulate prostate cancer progression.

Patel R, Gao M, Ahmad I, Fleming J, Singh LB, Rai TS, McKie AB, Seywright M, Barnetson RJ, Edwards J, Sansom OJ, Leung HY.

J Clin Invest. 2013 Mar;123(3):1157-75. doi: 10.1172/JCI63672. Epub 2013 Feb 22.


Characterizing the contribution of stem/progenitor cells to tumorigenesis in the Pten-/-TP53-/- prostate cancer model.

Abou-Kheir WG, Hynes PG, Martin PL, Pierce R, Kelly K.

Stem Cells. 2010 Dec;28(12):2129-40. doi: 10.1002/stem.538.


Pten inactivation and the emergence of androgen-independent prostate cancer.

Shen MM, Abate-Shen C.

Cancer Res. 2007 Jul 15;67(14):6535-8. Review.


The pace of prostatic intraepithelial neoplasia development is determined by the timing of Pten tumor suppressor gene excision.

Luchman HA, Benediktsson H, Villemaire ML, Peterson AC, Jirik FR.

PLoS One. 2008;3(12):e3940. doi: 10.1371/journal.pone.0003940. Epub 2008 Dec 15.


Sprouty genes function in suppression of prostate tumorigenesis.

Schutzman JL, Martin GR.

Proc Natl Acad Sci U S A. 2012 Dec 4;109(49):20023-8. doi: 10.1073/pnas.1217204109. Epub 2012 Nov 13.


IB1/JIP-1 controls JNK activation and increased during prostatic LNCaP cells neuroendocrine differentiation.

Tawadros T, Martin D, Abderrahmani A, Leisinger HJ, Waeber G, Haefliger JA.

Cell Signal. 2005 Aug;17(8):929-39. Epub 2005 Mar 3.


A reduction in Pten tumor suppressor activity promotes ErbB-2-induced mouse prostate adenocarcinoma formation through the activation of signaling cascades downstream of PDK1.

Rodriguez OC, Lai EW, Vissapragada S, Cromelin C, Avetian M, Salinas P, Ramos H, Kallakury B, Casimiro M, Lisanti MP, Tanowitz HB, Pacak K, Glazer RI, Avantaggiati M, Albanese C.

Am J Pathol. 2009 Jun;174(6):2051-60. doi: 10.2353/ajpath.2009.080859. Epub 2009 May 14.


Conditional deletion of the Pten gene in the mouse prostate induces prostatic intraepithelial neoplasms at early ages but a slow progression to prostate tumors.

Kwak MK, Johnson DT, Zhu C, Lee SH, Ye DW, Luong R, Sun Z.

PLoS One. 2013;8(1):e53476. doi: 10.1371/journal.pone.0053476. Epub 2013 Jan 8.


Roles of the RAF/MEK/ERK and PI3K/PTEN/AKT pathways in malignant transformation and drug resistance.

McCubrey JA, Steelman LS, Abrams SL, Lee JT, Chang F, Bertrand FE, Navolanic PM, Terrian DM, Franklin RA, D'Assoro AB, Salisbury JL, Mazzarino MC, Stivala F, Libra M.

Adv Enzyme Regul. 2006;46:249-79. Epub 2006 Jul 18.


Pten loss and RAS/MAPK activation cooperate to promote EMT and metastasis initiated from prostate cancer stem/progenitor cells.

Mulholland DJ, Kobayashi N, Ruscetti M, Zhi A, Tran LM, Huang J, Gleave M, Wu H.

Cancer Res. 2012 Apr 1;72(7):1878-89. doi: 10.1158/0008-5472.CAN-11-3132. Epub 2012 Feb 20.


Conditional expression of the androgen receptor induces oncogenic transformation of the mouse prostate.

Zhu C, Luong R, Zhuo M, Johnson DT, McKenney JK, Cunha GR, Sun Z.

J Biol Chem. 2011 Sep 23;286(38):33478-88. doi: 10.1074/jbc.M111.269894. Epub 2011 Jul 27.


Heterogeneous tumor evolution initiated by loss of pRb function in a preclinical prostate cancer model.

Hill R, Song Y, Cardiff RD, Van Dyke T.

Cancer Res. 2005 Nov 15;65(22):10243-54.


Up-regulation of MKK4, MKK6 and MKK7 during prostate cancer progression: an important role for SAPK signalling in prostatic neoplasia.

Lotan TL, Lyon M, Huo D, Taxy JB, Brendler C, Foster BA, Stadler W, Rinker-Schaeffer CW.

J Pathol. 2007 Aug;212(4):386-94.

Items per page

Supplemental Content

Write to the Help Desk